43 results on '"Oliva, Esther N"'
Search Results
2. Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations
3. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
4. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes
5. Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome
6. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1
7. Development and validation of QOL-E© instrument for the assessment of health-related quality of life in myelodysplastic syndromes
8. Pharmacokinetic / Pharmacodynamic (PK/PD) Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia
9. Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality
10. Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice
11. Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO
12. Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study
13. Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome
14. Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity
15. Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study
16. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion
17. More Concern About Transfusion Requirement When Evaluating Quality of Life in Anemic Patients
18. Outcome of therapy-related myeloid neoplasms treated with azacitidine
19. Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study
20. The Real-World Incidence of Relapse in Acute Myeloid Leukemia (AML): A Systematic Literature Review (SLR)
21. A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in the Treatment of Anemia in Patients with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndromes (MDS)
22. A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes
23. Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence
24. Prospective changes of cardiac iron and function in low and intermediate-1 risk mds patients
25. Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy
26. Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine
27. Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide
28. Unexpected Erythroid and Cytogenetic Responses After Discontinuation of a Short Course of Lenalidomide As a Result of Severe Skin Rash in a Patient With 5q Syndrome
29. Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life
30. Changes in Gene Expression Profiles during Treatment with Erythropoetic Growth Factors in Myelodysplastic Syndromes.
31. Treatment of Anemia of Myelodysplastic Syndromes and Improvements in Cardiac Geometry.
32. Risk Factors for Cardiovascular Events in Myeloproliferative Syndromes.
33. Quality of Life in Elderly Patients with Acute Myeloid Leukemia.
34. Darbepoetin for the Treatment of Anemia of Myelodysplastic Syndromes: Efficacy and Improvements in Quality of Life.
35. Quality of Life in Elderly Patients with Acute Myeloid Leukemia.
36. Hemoglobin Level Threshold in Myelodysplastic Syndrome: Cardiac Hypertrophy and Quality of Life.
37. Darbepoetin Efficacy in Myelodysplastic Syndrome.
38. Quality of life in myelofibrosis with myeloid metaplasia: a cross-sectional study
39. Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine.
40. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.
41. Costs and quality of life in patients with myelodysplastic syndromes.
42. Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians.
43. A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.